Hormones, health, and the dual burden: how women experience parkinson’s differently

Recent insights from experts at Baptist Health, including Dr Sameea Husain-Wilson and Dr Sarah Marmol, have highlighted that the experience of Parkinson’s is significantly shaped by biological sex and hormonal history. While the condition is more common in men, women face a unique clinical path influenced by estrogen levels, specific symptom patterns, and a disproportionate social burden. The power of estrogen and the impact of menopause Research suggests that estrogen may offer a natural protective effect on the brain’s dopamine-producing pathways. This hormone helps regulate how dopamine is made and used, while also acting as an antioxidant to protect brain cells. Because of this, women often have a lower lifetime risk of the condition than men and may be diagnosed slightly later in life. However, the transition into menopause marks a significant turning point. Studies indicate that a shorter lifetime exposure to estrogen—whether due to early menopause or surgical menopause—is linked to an increased risk of Parkinson’s and an earlier onset of symptoms. Many women report that their symptoms become more noticeable or their medication feels less effective during hormonal shifts, yet these cyclic changes are often overlooked in standard clinical settings. Differing symptoms: women vs men The way the condition manifests varies notably between the sexes. Men are more likely to experience rigidity, stiffness, and significant issues with gait and balance. They also tend to face higher rates of cognitive impairment and REM sleep behaviour disorder, where they physically act out dreams. In contrast, women are more likely to experience: Motor Complications: Higher rates of dyskinesia (involuntary movements) and "off" periods where medication wears off unexpectedly. Non-motor Symptoms: A greater burden of anxiety, depression, fatigue, and physical pain. Perceived Disability: Although the physical rate of progression is often similar to men, women frequently report a lower quality of life, largely driven by mood symptoms and the social pressures they face. gaps in research and clinical trials A major challenge in modern care is that women remain underrepresented in clinical trials. This lack of data has created several "blind spots" in how the condition is treated: Dosing Uncertainty: Women often have different body compositions and sensitivities to medication, yet most dosing guidelines are based on research dominated by male participants. Hormone Interactions: There is very little formal guidance on how hormone replacement therapy (HRT) or menopausal status interacts with Parkinson's medications. Outcome Measures: Research often focuses on motor improvements, potentially ignoring symptoms like fatigue and emotional well-being, which women cite as high priorities. The dual burden of caregiving One of the most profound differences is the social role many women occupy. Women with Parkinson’s often continue to act as primary caregivers for their own spouses, elderly parents, or grandchildren, even as their own symptoms progress. This "dual burden" of managing a chronic condition while caring for others can lead to faster burnout and increased physical strain. Experts suggest a gender-informed approach to care. This includes naming and validating the strain of caregiving during medical appointments and linking symptom management directly to a woman’s ability to maintain her independence and social roles. By screening for caregiver burden early and offering concrete support—such as respite care or social work involvement—healthcare providers can better support the overall well-being of women living with the condition.